Gynecological cancers, including those affecting the ovaries, uterus, and cervix, represent a significant health burden for women. While survival rates have improved, many women experience chronic pelvic pain secondary to cancer treatment, especially radiotherapy and chemotherapy. This treatment-induced pelvic pain can be of difficult management and significantly affects patients' quality of life.
In our experience, ozone therapy has emerged as a promising complementary treatment for pain relief in patients with chronic diseases, including side effects of cancer treatment. However, the genetic and epigenetic mechanisms influencing its effectiveness have not yet been thoroughly studied.
The aim of this prospective study is to analyze how ozone therapy modulates the expression of certain genes and its impact on epigenetic clocks, which could help predict pain response.
Adult women (>=18 years old) with gynecological tumors treated with radiotherapy-chemotherapy.
Cancer disease is stable or in remission.
Life expectancy > = 6 months.
Patients included in the group of patients with pelvic pain must have a clinical, radiological, endoscopic, or histopathological diagnosis that their pain is not secondary to the oncological process.
Age < 18 years old.
Severe psychiatric disorders.
Inability to complete the quality of life questionnaires.
Active neoplasia requiring recent initiation (< 3 months) of systemic or local treatment.
Bernardino Clavo, MD, PhD
Lead sponsor
Dr. Negrin University Hospital
Sponsor institution
Fundacion Canaria Instituto de Investigacion Sanitaria de Canarias (FIISC)
Collaborator
Fundación DISA, Canary Islands, Spain
Collaborator
Council of Gran Canaria
Collaborator